Related Experiment Video
Updated: Aug 17, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series
1Department of Psychiatry, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA. thomas_Schwartz@yahoo.com
Abstract:
Tiagabine is currently approved by the Food and Drug Administration for use in treating certain forms of epilepsy. Like other anticonvulsant agents, tiagabine has been explored for use as a mood stabilizer and in panic disorder. This article presents a case series of five patients who were prescribed tiagabine for treatment-resistant anxiety.
More Related Videos
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Anxiolytic Drugs: Overview
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic circuitry.
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Drug Therapy
Antianxiety Medications
Electroconvulsive Therapy

